Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.50 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | IAPP | P10997 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966498 | 0.82 | ERN1 (0.55) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL30679775 | 0.78 | ERN1 (0.43) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL26116456 | 0.78 | ERN1 (0.43) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL1093604 | 0.76 | ERN1 (0.36) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL24605381 | 0.76 | ERN1 (0.58) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL15096091 | 0.75 | CA12 (0.42) | CA1CA2MEN1LMNATHRB | |
| SCHEMBL5634372 | 0.75 | ERN1 (0.47) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL4304730 | 0.74 | NR1H2 (0.39) | CA2LMNATSHR | |
| SCHEMBL26113048 | 0.74 | ERN1 (0.50) | ERN1TLR2TLR1TLR6CA1 | |
| SCHEMBL26117414 | 0.74 | ERN1 (0.50) | ERN1TLR2TLR1TLR6CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206704-A1 | ENGINEERED IONOPHORES FOR TRANSPORT OF METAL IONS | NATIONAL INSTITUTES OF HEALTH | 2025-06-26 | — | — | US | disclosed |
| WO-2023183559-A1 | ENGINEERED IONOPHORES FOR TRANSPORT OF METAL IONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2364984-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2114958-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | Vertex Pharmceuticals Incorporated (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008106139-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| EP-1917269-A2 | INHIBITORS OF SERINE PROTEASES | Vertex Pharmaceuticals Incorporated (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007025307-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206704-A1 | ENGINEERED IONOPHORES FOR TRANSPORT OF METAL IONS | SLC7A1, SLC47A2, SLC39A14 | ERN1 3464/4885TLR2 3427/4885TLR1 4148/4885 |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | ERN1 236/4885TLR2 4586/4885TLR1 2632/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | ERN1 236/4885TLR2 4586/4885TLR1 2632/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | ERN1 273/4885TLR2 4670/4885TLR1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.